Prognosis of the individual course of disease: the elements of time, hetereogeneity and precision

被引:27
作者
Daumer, Martin [1 ]
Neuhaus, Anneke [1 ]
Herbert, Joseph [2 ]
Ebers, George [3 ]
机构
[1] Sylvia Lawry Ctr MS Res, D-81677 Munich, Germany
[2] NYU, Hosp Joint Dis, New York, NY USA
[3] Univ Oxford, Dept Clin Neurol, Oxford, England
关键词
Multiple sclerosis; Clinical trials; Actimetry; Disease progression; Outcome measure; Prognosis; MULTIPLE-SCLEROSIS DATABASE; CLINICAL-TRIALS; DISABILITY; SEVERITY; VALIDATION; STEPS; SCORE; MRI;
D O I
10.1016/S0022-510X(09)71301-2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
There is no gold standard in monitoring disease activity for clinical trials in multiple sclerosis. Various outcome measures, including relapses, disability and magnetic resonance imaging (MRI) measures have been used to demonstrate the efficacy of the different available therapies for Multiple sclerosis. Recently, the potential limitations of these measures have received increasing attention, and these have stimulated research into more appropriate and sensitive outcome measures for clinical trials. For example, it has been shown that widely-used MRI measures add little, if any, independent information to that provided by more clinically relevant measures such as relapses and disability. Similarly, the Expanded Disability status Scale (EDSS), which is the most widely-used measure of disability related to multiple sclerosis, is insufficiently sensitive to detect robust changes in disability over the timeframes usually used in clinical trials. An alternative to the EDSS is the Multiple Sclerosis Severity Score (MSSS), a severity scale which relates clinical disability to disease duration. The MSSS was originally developed from a database of nearly ten thousand patients from eleven European countries and Australia and has since been reproduced in an independent dataset of 1134 patients from the placebo arms of randomised clinical trials. Based on the MSSS score, disease severity can be defined, which shows stability over time and may provide evidence-based decision support for patient management. Another alternative to measure disability is the objective quantification of physical activity. There is evidence that recent developments in pervasive computing using tiny accelerometers may have the potential to increase the reliability and precision of motor assessment, especially in the mid-range of the EDSS. The outcome measures discussed have potential use as online tools for evidence-based decision support which are increasingly being used in medical research and clinical decision-making. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:S50 / S55
页数:6
相关论文
共 12 条
[1]   Prognosis of the individual course of disease - steps in developing a decision support tool for Multiple Sclerosis [J].
Daumer, M. ;
Neuhaus, A. ;
Lederer, C. ;
Scholz, M. ;
Wolinsky, J. S. ;
Heiderhoff, M. .
BMC MEDICAL INFORMATICS AND DECISION MAKING, 2007, 7 (1)
[2]   MRI as an outcome in multiple sclerosis clinical trials [J].
Daumer, M. ;
Neuhaus, A. ;
Morrissey, S. ;
Hintzen, R. ;
Ebers, G. C. .
NEUROLOGY, 2009, 72 (08) :705-711
[3]   Steps towards a miniaturized, robust and autonomous measurement device for the long-term monitoring of patient activity: ActiBelt [J].
Daumer, Martin ;
Thaler, Kathrin ;
Kruis, Esther ;
Feneberg, Wolfgang ;
Staude, Gerhard ;
Scholz, Michael .
BIOMEDIZINISCHE TECHNIK, 2007, 52 (01) :149-155
[4]  
Daumer M, 2008, MULT SCLER, V14, pS187
[5]   Reducing the probability of false positive research findings by pre-publication validation - Experience with a large multiple sclerosis database [J].
Daumer, Martin ;
Held, Ulrike ;
Ickstadt, Katja ;
Heinz, Moritz ;
Schach, Siegfried ;
Ebers, George .
BMC MEDICAL RESEARCH METHODOLOGY, 2008, 8 (1)
[6]   Disability as an outcome in MS clinical trials [J].
Ebers, G. C. ;
Heigenhauser, L. ;
Daumer, M. ;
Lederer, C. ;
Noseworthy, J. H. .
NEUROLOGY, 2008, 71 (09) :624-631
[7]  
Güntner M, 2008, MULT SCLER, V14, pS67
[8]   The multiple sclerosis severity score (MSSS) predicts disease severity over time [J].
Pachner, Andrew R. ;
Steiner, Israel .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 278 (1-2) :66-70
[9]  
RASHID A, 2009, 54 JAHR DTSCH GES ME, DOI DOI 10.3205/09G7DS246
[10]   Multiple sclerosis severity score -: Using disability and disease duration to rate disease severity [J].
Roxburgh, RHSR ;
Seaman, SR ;
Masterman, T ;
Hensiek, AE ;
Sawcer, SJ ;
Vukusic, S ;
Achiti, I ;
Confavreux, C ;
Coustans, M ;
le Page, E ;
Edan, G ;
McDonnell, GV ;
Hawkins, S ;
Trojano, M ;
Liguori, M ;
Cocco, E ;
Marrosu, MG ;
Tesser, F ;
Leone, MA ;
Weber, A ;
Zipp, F ;
Miterski, B ;
Epplen, JT ;
Oturai, A ;
Sorensen, PS ;
Celius, EG ;
Lara, NT ;
Montalban, X ;
Villoslada, P ;
Silva, AM ;
Marta, M ;
Leite, I ;
Dubois, B ;
Rubio, J ;
Butzkueven, H ;
Kilpatrick, T ;
Mycko, MP ;
Selmaj, KW ;
Rio, ME ;
Sá, M ;
Salemi, G ;
Savettieri, G ;
Hillert, J ;
Compston, DAS .
NEUROLOGY, 2005, 64 (07) :1144-1151